Index · Artikel · Studies show how skin cancer evades promising drug

Studies show how skin cancer evades promising drug

2010-11-24 2
   
Advertisement
résuméCHICAGO U.S. researchers have uncovered several ways in which melanoma can outsmart a promising experimental cancer pill called PLX4032, a finding that could lead to new drugs to keep the deadly skin cancer at bay, the teams said on Wednesday. Resear
Advertisement

Studies show how skin cancer evades promising drug


CHICAGO U.S. researchers have uncovered several ways in which melanoma can outsmart a promising experimental cancer pill called PLX4032, a finding that could lead to new drugs to keep the deadly skin cancer at bay, the teams said on Wednesday.

Researchers at the University of California, Los Angeles discovered two different resistance mechanisms that explain how melanoma stops responding to treatment with PLX4032, and a separate team at the Broad Institute of Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, discovered a third.

They said the findings may lead to drug cocktails that could extend the effectiveness of PLX4032, a drug being co-developed by privately held biotechnology company Plexxikon and Roche.

Up to 80 percent of patients with a genetic mutation in the BRAF gene respond to PLX4032, but the effect lasts only seven to nine months for most patients.

"The question is, when these patients relapse, 'What happens?'" said Dr. Roger Lo of UCLA, who worked on one the two studies published on Wednesday in the journal Nature.

Lo and colleagues at UCLA have been studying changes in cancer tumors taken from patients before and after treatment with PLX4032. The hope is to pin down exactly how the cancer is outsmarting the medication, Lo said in a telephone interview.

PLX4032 belongs to a new class of drugs that target tumor cells with a mutation in a gene called BRAF. The mutations occur in 50 percent to 60 percent of melanoma patients.

Lo's team initially suspected the cancer was developing additional BRAF mutations to get around the drug because that is how many cancers elude targeted drugs.

"You hit it with an axe, but the cancer soon finds a way to mitigate the effects of the axe," Lo said in a statement.

The team found no secondary mutations.

Instead, they found that in some patients, the cancer acquired resistance to PLX4032 by making too much of a protein on the outside of cancer cells that allowed it to survive. In another, they found mutations in a gene called NRAS that allowed the cancer to short-circuit the BRAF mutation, making the drug obsolete.

"We have 16 resistant tumors studied in this work. They come from 12 separate patients from both Phase I and Phase II trials. What we find is there are distinct mechanisms that offer different types of escape," Lo said.

He said the two mechanisms they discovered account for about 40 percent of the cases of resistance studied by the team, and he thinks there will be several more.

In a separate study, a team led by Levi Garraway and colleagues of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT found that in some patients treated with PLX4032, a cancer gene called COT -- also known as MAP3K8 -- drives resistance.

They found elevated levels of a protein made by the COT gene in samples from three patients with advanced melanoma who were treated with the drug PLX4032.

"We have no doubt that other resistance mechanisms are also going to be important in B-RAF mutant melanoma, but by taking a systematic approach, we should be able to find them," Garraway said in a statement.

Lo said many of the survival pathways used by the cancer can be attacked with existing cancer drugs or drugs that are being studied in clinical trials.

By tracking these down, he thinks, researchers will be able to develop a cocktail of drugs that will attack the cancer and cut off its escape routes, turning the most deadly of skin cancers into a chronic disease, much like drug cocktails have done for the treatment of AIDS.

Plexxikon and Roche are enrolling patients in a Phase III clinical trial of the drug, which is typically the final stage of human testing before a new drug is submitted to regulators for an approval decision.

(Editing by Mohammad Zargham)

  • Studies show how skin cancer evades promising drug

    Studies show how skin cancer evades promising drug
    CHICAGO U.S. researchers have uncovered several ways in which melanoma can outsmart a promising experimental cancer pill called PLX4032, a finding that could lead to new drugs to keep the deadly skin cancer at bay, the teams said on Wednesday. Resear
    2010-11-24 CANCERPILLRELAPSE
  • Common skin cancer drug smoothes wrinkles: study

    Common skin cancer drug smoothes wrinkles: study
    CHICAGO A cream used to treat the early signs of skin cancer may erase wrinkles and leave behind younger-looking skin, U.S. researchers said on Monday. They said Valeant Pharmaceuticals' cream Efudex, which is used to treat actinic keratoses, a preca
    2009-06-16 CANCERSKIN
  • Skin cancer can be inherited: studies

    Skin cancer can be inherited: studies
    NEW YORK (Reuters Health) - Want to reduce your risk of skin cancer? Wear sun screen, of course. But two new studies suggest that choosing your relatives carefully could also be helpful. One found that having an identical twin with melanoma increased
    2009-10-10 CANCERSKIN
  • Positive skin cancer drug data boosts Roche

    Positive skin cancer drug data boosts Roche
    ZURICH Roche's new cancer drug vismodegib could help patients with a potentially fatal skin cancer type, positive mid-stage trial results showed, going some way to lift confidence in the drugmaker after a rough 2010. Roche is struggling to find its f
    2011-03-21 ROCHE
  • FDA approves Roche skin cancer drug Zelboraf

    FDA approves Roche skin cancer drug Zelboraf
    WASHINGTON U.S. drug regulators on Wednesday approved a targeted skin cancer drug from Roche Holding along with its diagnostic test, an advance in personalized health care. The Food and Drug Administration was two months ahead of schedule in approvin
    2011-08-17 ROCHEZELBORAF
  • FDA approves Roche skin cancer drug

    FDA approves Roche skin cancer drug
    n">U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma. The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food
    2012-01-30 ROCHEAPPROVAL
  • Roche gets Swiss approval for skin cancer drug

    Roche gets Swiss approval for skin cancer drug
    ZURICH Swiss drugmaker Roche Holding AG has received Swiss approval for Erivedge, the first medicine for people with advanced forms of basal cell carcinoma, the most common skin cancer. Roche, the world's largest maker of cancer drugs, said about 10,
    2013-06-11 ROCHECARCINOMA
  • Roche skin cancer drug meets main goal in combination study

    Roche skin cancer drug meets main goal in combination study
    ZURICH An experimental drug from Roche helped people with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment, the Swiss drugmaker said on Monday. Pharmaceutical companies are lo
    2014-07-14 ROCHEDRUGS
  • FDA approves Novartis's advanced skin cancer drug

    FDA approves Novartis's advanced skin cancer drug
    n">The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. The drug, Odomzo, carry a boxed warning to alert the risks that it may cause death or severe birth defects in a develo
    2015-07-24 FDANOVARTIS
  • Novartis gets FDA approval for skin cancer drug combination

    Novartis gets FDA approval for skin cancer drug combination
    n">Novartis AG said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based
    2015-11-20 FDANOVARTIS
  • German Merck, Pfizer immunotherapy shows promise in rare skin cancer

    German Merck, Pfizer immunotherapy shows promise in rare skin cancer
    n">Germany's Merck KGaA (MRCG.DE) on Wednesday reported encouraging interim data against a rare and aggressive form of skin cancer from a mid-stage trial of its experimental drug that helps the immune system attack tumors. In the 61-patient study,
    2016-05-18 CANCERHEALTHMERCK
  • Tanning may up skin cancer risk for palest kids

    Tanning may up skin cancer risk for palest kids
    NEW YORK (Reuters Health) - Very light-skinned children who tan in the sun develop significantly more moles than their peers who stay pale in the sun, new research shows. The number of moles a person has is among the strongest risk factors for develo
    2009-09-22 CANCERTANNING
  • Should your hairdresser screen you for skin cancer?

    Should your hairdresser screen you for skin cancer?
    NEW YORK (Reuters Health) - Next time you get a haircut, you might end up with something you didn't expect: a referral to a dermatologist. A survey of Texas hair salons out today found more than a third of stylists check at least half of their custom
    2011-10-17 HAIRDRESSER
  • Some tanners return to the booth after skin cancer

    Some tanners return to the booth after skin cancer
    NEW YORK (Reuters Health) - One in seven people goes back to a tanning bed after being diagnosed with skin cancer, according to a new research letter. Indoor tanning is known to increase a person's risk for cancer. "The situation may be analogous to
  • Tanning beds must carry skin cancer warning: U.S. FDA

    Tanning beds must carry skin cancer warning: U.S. FDA
    n">The U.S. Food and Drug Administration is strengthening its regulation of tanning beds, which have been shown to increase the risk of skin cancer. The FDA, which is reclassifying sun lamp products from low risk to moderate risk, said on Thursday
    2014-05-29 FDATANNING
  • FDA panel recommends approval for Amgen's skin cancer immunotherapy

    FDA panel recommends approval for Amgen's skin cancer immunotherapy
    n">Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting
    2015-04-29 FDAAmgen
  • Roche skin cancer combination therapy gets EU panel backing

    Roche skin cancer combination therapy gets EU panel backing
    ZURICH Roche is expecting the European Commission this year to issue a final decision on a drug combination to treat advanced skin cancer, based on a drug panel's positive opinion made public on Friday. The European Union's Committee for Medicinal Pr
    2015-09-25 CANCERROCHECOMBO
  • Panel backs skin cancer advice for youths

    Panel backs skin cancer advice for youths
    NEW YORK (Reuters Health) - A government-backed expert panel joined in the fight against skin cancer on Tuesday with a proposal urging doctors to counsel fair-skinned youths about sun protection. "The definition of fair skin is it doesn't tan very we
    2011-11-08 CANCER
  • Tanning beds raise risk of common skin cancer: study

    Tanning beds raise risk of common skin cancer: study
    n">Tanning beds have already been linked to an increased risk of the deadliest type of skin cancer and now new research shows they can also raise the odds of developing the most common form of the disease. Scientists at the Yale School of Public H
    2011-12-13 CANCERTANNINGBEDS
  • Could mobile devices raise skin cancer risk?

    Could mobile devices raise skin cancer risk?
    n">(Reuters Health) - Devices like tablets, smartphones and laptops can reflect ultraviolet light from the sun and may indirectly increase users' exposure to the cancer-causing wavelengths, according to a new study. "These devices are general

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated